 |
Indication & Dosage |
| |
| |
| Intravenous |
| ACUTE MYELOID LEUKAEMIA |
| Adult:
12 mg/m2 daily for 5 days to induce remission. Alternatively, 12 mg/m2 for 3 days in combination with cytarabine. |
| |
| Intravenous |
| BREAST CANCER |
| Adult:
Initially, 14 mg/m2, then repeat every 3 wk. Adjust subsequent dose according to degree of myelosuppression. Debilitated patients or those who had previous chemotherapy: May reduce initial dose to 12 mg/m2. As part of a combination regimen: May reduce initial dose to 10-12 mg/m2. |
| |
| Intravenous |
| PROSTATIC CANCER |
| Adult:
12 mg/m2 daily for 5 days to induce remission. Alternatively, 12 mg/m2 for 3 days in combination with cytarabine. |
| |
| Intravenous |
| LYMPHOMA |
| Adult:
12 mg/m2 daily for 5 days to induce remission. Alternatively, 12 mg/m2 for 3 days in combination with cytarabine. |
| |
| Intravenous |
| LIVER CANCER |
| Adult:
12 mg/m2 daily for 5 days to induce remission. Alternatively, 12 mg/m2 for 3 days in combination with cytarabine. |
| |
| Intravenous |
| MULTIPLE SCLEROSIS |
| Adult:
12 mg/m2 daily for 5 days to induce remission. Alternatively, 12 mg/m2 for 3 days in combination with cytarabine. |
|
| |
|
| Precautions |
Preexisting myelosuppression. Perform periodic blood counts. Monitor cardiac function, especially after a cumulative dose of >160 mg/m2 and in patients with prior radiotherapy of the chest and concomitant cytotoxic therapy. Hepatic impairment. Discontinue admin if extravasation occurs. May impair ability to drive or operate machinery. |
| |
|
Potentially Life-threatening
Adverse Drug Reactions |
Arrhythmia, oedema, ECG changes; pain, fatigue, fever, headache; alopecia, nail bed changes; amenorrhoea, menstrual disorder, hyperglycaemia; abdominal pain, anorexia, nausea, constipation, diarrhoea, GI bleeding, mucositis, stomatitis, dyspepsia, vomiting, wt gain/loss; abnormal urine, UTI; haematologic disorders; elevated LFTs; weakness; increased BUN and creatinine, haematuria; cough, dyspnoea, upper respiratory tract infection; fungal infection, infection, sepsis. |
| |
|
| Adverse Drug Reactions |
Myelosuppression; cardiotoxicity. |
| |
|
| Interactions |
Impaired immune response to vaccines may occur; infection after admin of live vaccines in patients on immunosuppressants is also possible. |
| |
|
|
|
